Befotertinib clinical trials
Also written D-0316.
How each study uses befotertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the befotertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 5
Betta Pharmaceuticals Co., Ltd. (4) · InventisBio Co., Ltd (2) · Zhou Chengzhi (1) · Hebei Medical University Fourth Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Fudan University (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test befotertinib.
- May 2027Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC PatientsPhase 4 · Fudan University
- Jun 2027Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLCPhase 2 · Second Affiliated Hospital, School of Medicine, Zhejiang University
Studies
Open first, then newest update. How each study uses befotertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2Not yet recruitingPhase 4Zhou ChengzhiNCT07900243Written as Befotertinib
- ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With RadiotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07410611Written as Befotertinib
- Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIRecruitingPhase 2Betta Pharmaceuticals Co., Ltd.NCT07181499Written as Befotertinib
- Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLCRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06863506Written as befotertinib
- Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC PatientsRecruitingPhase 4Fudan UniversityNCT06561620Written as Befotertinib
- Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsRecruitingPhase 2Sun Yat-sen UniversityNCT06517953Written as Befotertinib
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedPhase 2/3Betta Pharmaceuticals Co., Ltd.NCT04206072Written as D-0316 Capsule
- Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingPhase 2Betta Pharmaceuticals Co., Ltd.NCT05007938Written as Befotertinib
- D-0316 in Patients With EGFR Positive Non Small Cell Lung CancerCompletedPhase 2InventisBio Co., LtdNCT03861156Written as D-0316
- D-0316 First Time in Patients Ascending Dose StudyCompletedPhase 1InventisBio Co., LtdNCT03452150Written as D-0316
- The Absorption, Metabolism and Excretion of [14C]D-0316 in HumanStatus unknownPhase 1Betta Pharmaceuticals Co., Ltd.NCT04464551Written as [14C]D-0316 suspension
Given beside what is tested · 1 — befotertinib is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call befotertinib · ClinicalTrials.gg INT002119
- UNII (FDA) 0XT2CPR891BEFOTERTINIBOne source FDA
- NCI Thesaurus C175747BefotertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0XT2CPR891 | BEFOTERTINIB | One source FDA |
| NCI Thesaurus | C175747 | Befotertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.